Latest news and updates from Sathgen Therapeutics

      July 20th, 2023

  • We completed the dosing of the first patient cohort with our lead anti-cancer drug, MSP008-22, a phase 1 clinical trial carried out in patients with advanced solid tumors. This milestone was covered as press releases in India, USA, UK, Germany, Spain, France.

      May 2023

  • We showcased our work on the anti-cancer drugs at the Pharma Partnering Summit in San Diego, CA, USA, a conference that brings together the pharmaceutical and biotech worlds.

     April 2023

  • The healthy volunteer trial entitled “A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers” was initiated in April 2023.

     January 2023

  • Our first-in-human patient trial entitled “A Single Ascending Dose, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetic Profile of MSP008-22 in Patients with Advanced Solid Tumors” was initiated in January 2023.

      December 2017

  • Patent for MSP008-22 anti-cancer compound granted in USA and Japan.

     June 2011

  • Patent for Synthesis of Cleistanthin A and its derivatives thereof granted in India, USA, Germany, Netherlands, France,
    UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada.

      February 2009

  • Patent for Process for Synthesis of Cleistanthin granted in India, Australia, New Zealand, Mexico, Canada, UK, France, Netherlands, Germany, and South Africa.
Scroll to top